Table 3.

Assessment on the RISC population of the performance of the available platinum-stratified Cox models for OS, in terms of discrimination (Harrell c-index), calibration (calibration slope) and accuracy (Schemper and Henderson Dx).

Model	Development cohort		Validation cohort
	All patients	Cisplatin only	All patients	Cisplatin only
Bajorin, 1999* [6]
c-index (95% CI)‡ calibration slope (95% CI) Dx	0.643 (0.613–0.672)	0.622 (0.584–0.660)	0.623 (0.579–0.666) 0.845 (0.683–1.045) 0.541	0.619 (0.563–0.675) 0.762 (0.542–1.071) 0.566
Apolo, 2013* [7]
c-index (95%CI)‡ calibration slope (95% CI) Dx	0.659 (0.629–0.689)	0.642 (0.603–0.681)	0.636 (0.592–0.679) 0.854 (0.695–1.049) 0.540	0.641 (0.583–0.698) 0.798 (0.575–1.108) 0.564
Galsky, 2013* [8]
c-index (95% CI)‡ calibration slope (95% CI) Dx	0.666 (0.635–0.696)	0.657 (0.617–0.696)	0.644 (0.600–0.688) 0.841 (0.674–1.049) 0.542	0.645 (0.587–0.702) 0.778 (0.553–1.094) 0.564
Present
c-index (95%CI)‡ calibration slope (95% CI) Dx	0.671 (0.641–0.701)		0.660 (0.617–0.704) 0.881 (0.715–1.087) 0.534

Abbreviations: CI: confidence interval; OS: overall survival; RISC: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium.

^*Type of chemotherapy (cisplatin vs carboplatin) being included into the original model as a covariate.

^‡estimated at 36 months